First-in-human: Single Ascending Dose, Food Effect, Drug-drug Interaction, Multiple Ascending Dose, Proof of Pharmacology
NCT ID: NCT02420782
Last Updated: 2016-07-01
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE1
Total Enrollment
116 participants
Study Classification
INTERVENTIONAL
Study Start Date
2015-05-31
Study Completion Date
2016-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple ascending oral doses of ASP6282 in healthy male and female subjects. 1 cohort (elderly) receives also a midazolam dosing.
This study will also explore the effect of itraconazole (another drug) on the PK of ASP6282, as well as to evaluate the safety and tolerability of ASP6282 alone and in combination with itraconazole in healthy male and female subjects.
Also, this study is to evaluate the PD and PK effects of single oral doses of ASP6282 on pilocarpine-induced salivation and pupil diameter in healthy nonelderly male and female subjects.
This study will also explore the effect of itraconazole (another drug) on the PK of ASP6282, as well as to evaluate the safety and tolerability of ASP6282 alone and in combination with itraconazole in healthy male and female subjects.
Also, this study is to evaluate the PD and PK effects of single oral doses of ASP6282 on pilocarpine-induced salivation and pupil diameter in healthy nonelderly male and female subjects.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP3700 in Healthy Male Subjects
NCT02155504
Healthy Volunteers
Pharmacokinetics of ASP3700
COMPLETED
PHASE1
A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP2205 in Healthy Young Males and Females and Elderly Females and to Evaluate the Effect of Food on the Pharmacokinetics of a Single Dose of of ASP2205
NCT02314793
Healthy Subjects
Pharmacokinetics of ASP2205
TERMINATED
PHASE1
Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP1617 in Healthy Adult Non-Asian and Japanese Subjects Including Assessment of a Food Effect
NCT04077879
Healthy Volunteers
COMPLETED
PHASE1
A Combined Single and Multiple Ascending Dose Study of ASP6858 in Healthy Subjects
NCT02359032
Healthy Volunteers
COMPLETED
PHASE1
A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K
NCT01387087
Healthy Subjects
Pharmacokinetics of ASP015K
COMPLETED
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study consists of three parts. Part 1 is Single Ascending Dose Including Food Effect and Drug-drug Interaction (DDI) with Itraconazole. There will be a washout between treatment period 1 and 2 in the DDI arm of Part 1; Part 2 is a Multiple Ascending Dose (MAD); Part 3, with a treatment period 1, 2 and 3 is Proof of Pharmacology. There will be a washout between each treatment period
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Healthy Volunteers
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
BASIC_SCIENCE
Blinding Strategy
DOUBLE
Participants
Investigators
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ASP6282 single ascending dose (fasted)
Part 1
Group Type
EXPERIMENTAL
ASP6282
Intervention Type
DRUG
oral
Placebo single ascending dose (fasted)
Part 1
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
DRUG
oral
ASP6282 single dose (fed)
Part 1
Group Type
EXPERIMENTAL
ASP6282
Intervention Type
DRUG
oral
Placebo single dose (fed)
Part 1
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
DRUG
oral
ASP6282 single dose (fasted)
Part 1 Period 1
Group Type
EXPERIMENTAL
ASP6282
Intervention Type
DRUG
oral
Itraconazole multiple dose and ASP6282 single dose (fasted)
Part 1 Period 2
Group Type
EXPERIMENTAL
ASP6282
Intervention Type
DRUG
oral
Itraconazole
Intervention Type
DRUG
oral
ASP6282 multiple ascending dose (nonelderly and elderly)
Part 2. Germany only: once daily dosing, optional twice daily dosing. Midazolam dosing elderly only, exploratory for DDI purpose
Group Type
EXPERIMENTAL
ASP6282
Intervention Type
DRUG
oral
Midazolam
Intervention Type
DRUG
oral
Placebo multiple ascending dose (nonelderly and elderly)
Part 2. Germany only: once daily dosing, optional twice daily dosing
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
DRUG
oral
ASP6282 and pilocarpine
Part 3
Group Type
EXPERIMENTAL
ASP6282
Intervention Type
DRUG
oral
Pilocarpine
Intervention Type
DRUG
oral
Placebo and pilocarpine
Part 3
Group Type
OTHER
Pilocarpine
Intervention Type
DRUG
oral
Placebo
Intervention Type
DRUG
oral
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ASP6282
oral
Intervention Type
DRUG
Itraconazole
oral
Intervention Type
DRUG
Pilocarpine
oral
Intervention Type
DRUG
Placebo
oral
Intervention Type
DRUG
Midazolam
oral
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Versed
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject has a body mass index (BMI) range of 18.5 to 30.0 kg/m2, inclusive. The subject weighs at least 50 kg \[screening\].
* Female subject must not donate ova starting at screening and throughout the clinical study period, and for 28 days after the final study drug administration.
* Male subject and his female spouse/partners who are of childbearing potential must be using highly effective contraception consisting of 2 forms of birth control (1 of which must be a barrier method) starting at screening and continue throughout the clinical study period, and for 90 days after the final study drug administration.
* Male subject must not donate sperm starting at screening and throughout the clinical study period, and for 90 days after last study drug administration.
* Subject agrees not to participate in another interventional study while participating in the present clinical study, defined as signing the informed consent form until completion of the last study visit.
Germany only:
* Female subject must either:
* Be of nonchildbearing potential:
1. Postmenopausal (defined as at least 1 year without any menses) prior to screening, or,
2. Documented surgically sterile.
* Or, if of childbearing potential:
1. Agree not to try to become pregnant during the clinical study and for 90 days after the final study drug administration,
2. Must have a negative serum pregnancy test at day -1, and
3. If heterosexually active, agree to consistently use a form of highly effective birth control in combination with a barrier method starting at screening and continuing throughout the clinical study period, and for 90 days after the final study drug administration.
4. Or agree to stay abstinent, if abstinence is the preferred and usual lifestyle of the subject, starting at screening and continuing throughout the clinical study period and for 90 days after the final study drug administration.
* Female subject must agree not to breastfeed starting at screening and throughout the clinical study period, and for 90 days after the final study drug administration.
* Female subject must not donate ova starting at screening and throughout the clinical study period, and for 90 days after the final study drug administration.
* Female subject must not donate ova starting at screening and throughout the clinical study period, and for 28 days after the final study drug administration.
* Male subject and his female spouse/partners who are of childbearing potential must be using highly effective contraception consisting of 2 forms of birth control (1 of which must be a barrier method) starting at screening and continue throughout the clinical study period, and for 90 days after the final study drug administration.
* Male subject must not donate sperm starting at screening and throughout the clinical study period, and for 90 days after last study drug administration.
* Subject agrees not to participate in another interventional study while participating in the present clinical study, defined as signing the informed consent form until completion of the last study visit.
Germany only:
* Female subject must either:
* Be of nonchildbearing potential:
1. Postmenopausal (defined as at least 1 year without any menses) prior to screening, or,
2. Documented surgically sterile.
* Or, if of childbearing potential:
1. Agree not to try to become pregnant during the clinical study and for 90 days after the final study drug administration,
2. Must have a negative serum pregnancy test at day -1, and
3. If heterosexually active, agree to consistently use a form of highly effective birth control in combination with a barrier method starting at screening and continuing throughout the clinical study period, and for 90 days after the final study drug administration.
4. Or agree to stay abstinent, if abstinence is the preferred and usual lifestyle of the subject, starting at screening and continuing throughout the clinical study period and for 90 days after the final study drug administration.
* Female subject must agree not to breastfeed starting at screening and throughout the clinical study period, and for 90 days after the final study drug administration.
* Female subject must not donate ova starting at screening and throughout the clinical study period, and for 90 days after the final study drug administration.
Exclusion Criteria
* Female subject who has been pregnant within 6 months prior to screening assessment or breastfeeding within 3 months prior to screening.
* Subject has a known or suspected hypersensitivity to ASP6282, itraconazole (part 1 - DDI only) or pilocarpine (part 3 - Proof of pharmacology (PoP) only) or any components of the formulations used.
* Subject uses a CYP3A4 metabolized substrate that can prolong the QT interval, e.g., astemizole, bepridil, cisapride, dofetilide, levacetylmethadol (levomethadyl), mizolastine, pimozide, quinidine, sertindole and terfenadine.
* Subject uses any of the following medication: atorvastatin, lovastatin and simvastatin, triazolam, midazolam, ergot alkaloids such as dihydroergotamine, ergometrine (ergonovine), ergotamine and methylergometrine (methylergonovine), eletriptan and nisodipine.
* Subject with evidence of ventricular dysfunction such as congestive heart failure or a history of congestive heart failure.
* Subject has clinically significant, cardiorenal disease, asthma and/or any other disease at risk for cholinergic agonists.
* Subject has a condition of the eye which could be affected by the intake of pilocarpine (e.g., acute iritis) (part 3 - PoP only).
* Subject has any of the liver chemistry tests (Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), alkaline phosphatase (ALP), gamma glutamyl transferase (GGT), Total bilirubin (TBL) above the Upper limit of normal (ULN)). In such a case, the assessment may be repeated once on Day -1 (in part 1 - DDI: treatment period 1 only).
* Subject has any clinically significant history of allergic conditions (including drug allergies, asthma, eczema or anaphylactic reactions, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
* Subject has chronic bronchitis and/or chronic obstructive pulmonary disease, or known or suspected cholelithiasis or biliary tract disease, or peptic ulceration or cognitive or psychiatric disturbances, or renal or hepatic insufficiency, or narrow-angle glaucoma.
* Subject has/had febrile illness or symptomatic, viral, bacterial (including upper respiratory infection) or fungal (noncutaneous) infection within 1 week prior to admission to the clinical unit on Day -1.
* Subject has any clinically significant abnormality following the investigator's review of the physical examination, ECG and clinical study protocol-defined clinical laboratory tests at screening or day -1.
* Subject has a mean pulse \< 40 or \> 90 bpm; mean systolic blood pressure (SBP) \> 140 mmHg; mean diastolic blood pressure (DBP) \> 90 mmHg (vital signs measurements taken in triplicate after subject has been resting in supine position for 5 minutes; pulse will be measured automatically) on admission to the clinical unit on Day -1. If the mean blood pressure exceeds the limits above, 1 additional triplicate can be taken.
* Subject has a mean corrected QT interval using Fridericia's formula (QTcF) \> 430 ms (for male subjects) and \> 450 ms (for female subjects) at screening. If the mean QTcF exceeds the limits above, 1 additional triplicate ECG can be taken at screening.
* Subject uses any prescribed or nonprescribed drugs (including vitamins, natural and herbal remedies, e.g., St. John's wort) in the 2 weeks prior to first study drug administration, except for occasional use of paracetamol (up to 2 g/day) (all parts) and except for use of contraceptives or hormone replacement therapy (except for part 1- DDI).
* Subject has a history of smoking within 6 months prior to first study drug administration on day 1.
* Subject has a history of drinking \> 21 units of alcohol/week for male subjects or \> 14 units of alcohol/week for female subjects (1 unit = 10 g pure alcohol = 250 mL of beer \[5%\] or 35 mL of spirits \[35%\] or 100 mL of wine \[12%\]) within 3 months prior to admission to the clinical unit on Day -1.
* Subject has consumed grapefruit/Seville oranges, grapefruit-containing products or Seville orange-containing products within 72 hours prior to admission to the clinical unit on Day -1.
* Subject uses any inducer of metabolism (e.g., barbiturates, rifampin) within 1 month prior to admission to the clinical unit on Day -1.
* Subject uses any drugs of abuse within 3 months prior to admission to the clinical unit on Day -1.
* Subject had significant blood loss, donated 1 unit (500 mL) of blood or more, or received a transfusion of any blood or blood products within 60 days or donated plasma within 7 days prior to admission to the clinical unit on Day -1.
* Subject has a positive serology test for hepatitis B surface antigen (HBsAg), hepatitis A virus antibodies (anti-HAV) (immunoglobulin M \[IgM\]), hepatitis C virus antibodies (anti-HCV), or antibodies to human immunodeficiency virus type 1 (HIV-1) and/or type 2 (HIV-2) at screening.
* Subject participated in any clinical study or has been treated with any investigational drugs within 90 days prior to screening.
Germany only:
* Subject has a mean pulse \< 50 or \> 90 bpm; mean systolic blood pressure (SBP) \> 140 mmHg; mean diastolic blood pressure (DBP) \> 90 mmHg (vital signs measurements taken in triplicate after subject has been resting in supine position for 5 minutes; pulse will be measured automatically) on admission to the clinical unit on day -1. (For elderly subjects the following criteria apply: SBP \> 160 mmHg and DBP \> 100 mmHg). If the mean blood pressure exceeds the limits above, 1 additional triplicate can be taken.
* Subject has a mean corrected QT interval using Fridericia's formula (QTcF) \> 430 ms (for male subjects) and \> 450 ms (for female subjects) at day -1. If the mean QTcF exceeds the limits above, 1 additional triplicate ECG can be taken at day -1.
* Subject has a positive serology test for hepatitis B surface antigen (HBsAg), hepatitis B core antibodies, hepatitis A virus antibodies (anti-HAV) (immunoglobulin M \[IgM\]), hepatitis C virus antibodies (anti-HCV), or antibodies to human immunodeficiency virus type 1 (HIV-1) and/or type 2 (HIV-2) at screening.
* Subject is unable to communicate, read and understand German, or has any other condition which, in the investigator's opinion, makes the subject unsuitable for clinical study participation.
* Subject is a vulnerable subject (e.g., subject kept in detention).
* Subject has a known or suspected hypersensitivity to ASP6282, itraconazole (part 1 - DDI only), pilocarpine (part 3 - PoP only) or midazolam (part 2 - elderly cohort only) or any components of the formulations used.
* Subject uses any prescribed or nonprescribed drugs (including vitamins, natural and herbal remedies, e.g., St. John's wort) in the 2 weeks prior to first study drug administration, except for occasional use of paracetamol (up to 2 g/day) (all parts) and except for use of hormone replacement therapy (except for part 1 - DDI).
* Subject has a known or suspected hypersensitivity to ASP6282, itraconazole (part 1 - DDI only) or pilocarpine (part 3 - Proof of pharmacology (PoP) only) or any components of the formulations used.
* Subject uses a CYP3A4 metabolized substrate that can prolong the QT interval, e.g., astemizole, bepridil, cisapride, dofetilide, levacetylmethadol (levomethadyl), mizolastine, pimozide, quinidine, sertindole and terfenadine.
* Subject uses any of the following medication: atorvastatin, lovastatin and simvastatin, triazolam, midazolam, ergot alkaloids such as dihydroergotamine, ergometrine (ergonovine), ergotamine and methylergometrine (methylergonovine), eletriptan and nisodipine.
* Subject with evidence of ventricular dysfunction such as congestive heart failure or a history of congestive heart failure.
* Subject has clinically significant, cardiorenal disease, asthma and/or any other disease at risk for cholinergic agonists.
* Subject has a condition of the eye which could be affected by the intake of pilocarpine (e.g., acute iritis) (part 3 - PoP only).
* Subject has any of the liver chemistry tests (Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), alkaline phosphatase (ALP), gamma glutamyl transferase (GGT), Total bilirubin (TBL) above the Upper limit of normal (ULN)). In such a case, the assessment may be repeated once on Day -1 (in part 1 - DDI: treatment period 1 only).
* Subject has any clinically significant history of allergic conditions (including drug allergies, asthma, eczema or anaphylactic reactions, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
* Subject has chronic bronchitis and/or chronic obstructive pulmonary disease, or known or suspected cholelithiasis or biliary tract disease, or peptic ulceration or cognitive or psychiatric disturbances, or renal or hepatic insufficiency, or narrow-angle glaucoma.
* Subject has/had febrile illness or symptomatic, viral, bacterial (including upper respiratory infection) or fungal (noncutaneous) infection within 1 week prior to admission to the clinical unit on Day -1.
* Subject has any clinically significant abnormality following the investigator's review of the physical examination, ECG and clinical study protocol-defined clinical laboratory tests at screening or day -1.
* Subject has a mean pulse \< 40 or \> 90 bpm; mean systolic blood pressure (SBP) \> 140 mmHg; mean diastolic blood pressure (DBP) \> 90 mmHg (vital signs measurements taken in triplicate after subject has been resting in supine position for 5 minutes; pulse will be measured automatically) on admission to the clinical unit on Day -1. If the mean blood pressure exceeds the limits above, 1 additional triplicate can be taken.
* Subject has a mean corrected QT interval using Fridericia's formula (QTcF) \> 430 ms (for male subjects) and \> 450 ms (for female subjects) at screening. If the mean QTcF exceeds the limits above, 1 additional triplicate ECG can be taken at screening.
* Subject uses any prescribed or nonprescribed drugs (including vitamins, natural and herbal remedies, e.g., St. John's wort) in the 2 weeks prior to first study drug administration, except for occasional use of paracetamol (up to 2 g/day) (all parts) and except for use of contraceptives or hormone replacement therapy (except for part 1- DDI).
* Subject has a history of smoking within 6 months prior to first study drug administration on day 1.
* Subject has a history of drinking \> 21 units of alcohol/week for male subjects or \> 14 units of alcohol/week for female subjects (1 unit = 10 g pure alcohol = 250 mL of beer \[5%\] or 35 mL of spirits \[35%\] or 100 mL of wine \[12%\]) within 3 months prior to admission to the clinical unit on Day -1.
* Subject has consumed grapefruit/Seville oranges, grapefruit-containing products or Seville orange-containing products within 72 hours prior to admission to the clinical unit on Day -1.
* Subject uses any inducer of metabolism (e.g., barbiturates, rifampin) within 1 month prior to admission to the clinical unit on Day -1.
* Subject uses any drugs of abuse within 3 months prior to admission to the clinical unit on Day -1.
* Subject had significant blood loss, donated 1 unit (500 mL) of blood or more, or received a transfusion of any blood or blood products within 60 days or donated plasma within 7 days prior to admission to the clinical unit on Day -1.
* Subject has a positive serology test for hepatitis B surface antigen (HBsAg), hepatitis A virus antibodies (anti-HAV) (immunoglobulin M \[IgM\]), hepatitis C virus antibodies (anti-HCV), or antibodies to human immunodeficiency virus type 1 (HIV-1) and/or type 2 (HIV-2) at screening.
* Subject participated in any clinical study or has been treated with any investigational drugs within 90 days prior to screening.
Germany only:
* Subject has a mean pulse \< 50 or \> 90 bpm; mean systolic blood pressure (SBP) \> 140 mmHg; mean diastolic blood pressure (DBP) \> 90 mmHg (vital signs measurements taken in triplicate after subject has been resting in supine position for 5 minutes; pulse will be measured automatically) on admission to the clinical unit on day -1. (For elderly subjects the following criteria apply: SBP \> 160 mmHg and DBP \> 100 mmHg). If the mean blood pressure exceeds the limits above, 1 additional triplicate can be taken.
* Subject has a mean corrected QT interval using Fridericia's formula (QTcF) \> 430 ms (for male subjects) and \> 450 ms (for female subjects) at day -1. If the mean QTcF exceeds the limits above, 1 additional triplicate ECG can be taken at day -1.
* Subject has a positive serology test for hepatitis B surface antigen (HBsAg), hepatitis B core antibodies, hepatitis A virus antibodies (anti-HAV) (immunoglobulin M \[IgM\]), hepatitis C virus antibodies (anti-HCV), or antibodies to human immunodeficiency virus type 1 (HIV-1) and/or type 2 (HIV-2) at screening.
* Subject is unable to communicate, read and understand German, or has any other condition which, in the investigator's opinion, makes the subject unsuitable for clinical study participation.
* Subject is a vulnerable subject (e.g., subject kept in detention).
* Subject has a known or suspected hypersensitivity to ASP6282, itraconazole (part 1 - DDI only), pilocarpine (part 3 - PoP only) or midazolam (part 2 - elderly cohort only) or any components of the formulations used.
* Subject uses any prescribed or nonprescribed drugs (including vitamins, natural and herbal remedies, e.g., St. John's wort) in the 2 weeks prior to first study drug administration, except for occasional use of paracetamol (up to 2 g/day) (all parts) and except for use of hormone replacement therapy (except for part 1 - DDI).
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astellas Pharma Europe B.V.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor
Role: STUDY_DIRECTOR
Clinical Pharmacology & Exploratory Development (CPED)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site DE49001
Berlin, , Germany
Site Status
Site GB44001
Harrow, , United Kingdom
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Germany
United Kingdom
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2015-000093-35
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
6282-CL-0001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Study to Assess the Safety, Tolerability, and Effects in and on the Body of Healthy Young and Elderly Male and Female Subjects of Ascending Multiple Oral Doses of ASP3652
NCT02243657
COMPLETED
PHASE1
A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP7713 in Healthy Non-Japanese Adult and Elderly Subjects and Healthy Japanese Adult Subjects
NCT03108755
COMPLETED
PHASE1
Study to Evaluate the Safety and Pharmacokinetics of ASP2151 in Healthy Non-elderly and Elderly Subjects
NCT02796118
COMPLETED
PHASE1
A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K
NCT01364974
COMPLETED
PHASE1
A Study to Assess the Safety, Pharmacological Effect and Plasma Concentration of ASP7991 After Single Oral Administration to Healthy Volunteers
NCT01675518
COMPLETED
PHASE1
Single + Multiple Ascending Dose and Food Effect Study of AZD7986 in Healthy Volunteers, PK, PD and Safety Study
NCT02303574
COMPLETED
PHASE1
AZD8529 Single Ascending Dose Study
NCT00755378
COMPLETED
PHASE1
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP3700 in Healthy Subjects
NCT02285465
WITHDRAWN
PHASE1
A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Multiple Ascending Doses of ASP7962 in Healthy Subjects
NCT02136316
COMPLETED
PHASE1
A Phase 1, 2-Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASLAN003 in Healthy Elderly Subjects
NCT02342652
COMPLETED
PHASE1
Study to Evaluate the Safety and Tolerability of ASP8062 in Healthy Japanese Male and Female Subjects
NCT03183739
COMPLETED
PHASE1
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP6294 Administered Intravenously or Subcutaneously in Healthy Young Male and Female Subjects
NCT02681861
COMPLETED
PHASE1
A Study to Assess Adverse Events and How Single and Multiple Ascending Doses of ABBV-903 Move Through the Body in Healthy Adults
NCT05691699
COMPLETED
PHASE1
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 After Single Ascending Doses to Healthy Males
NCT02484729
COMPLETED
PHASE1
A Clinical Trial to Investigate Safety and Tolerability of ASP7962 in Healthy Humans
NCT01981928
COMPLETED
PHASE1
A Study to Assess the Safety, Tolerability and Effects of Single and Multiple Ascending Doses of ASP1707 in Healthy Male and Pre-menopausal Female Subjects, Including a Comparison of the Effects Under Fasted and Fed Conditions in Healthy Young Male Subjects
NCT02368912
COMPLETED
PHASE1
A Study of AZD4205 in Healthy Adult Subjects
NCT03728023
COMPLETED
PHASE1
Assessment of the Safety, Tolerability and Pharmacokinetics of AV078 in Healthy Volunteers
NCT06205381
COMPLETED
PHASE1
Single Ascending Dose Study to Evaluate Pharmacokinetics and Food-Effect in Healthy Volunteers
NCT02853643
COMPLETED
PHASE1
A Study to Assess the Pharmacokinetics of AZD4831 When Administered Alone and in Combination With Itraconazole
NCT05236543
COMPLETED
PHASE1
A Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP2408 Following Single Intravenous Doses in Healthy Subjects
NCT02125435
COMPLETED
PHASE1
Study to Investigate Single Ascending Oral Doses of AZD5213 in Healthy Male and Non Fertile Female Subjects
NCT01121302
COMPLETED
PHASE1
Multiple Dose Escalating Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP1941
NCT01288898
COMPLETED
PHASE1
A Study to Assess the Effects of Single Ascending Doses of ASP1707 in Healthy Young Japanese Male Subjects
NCT02146742
COMPLETED
PHASE1